Canagliflozin-something new for type 2 diabetes, but is it safe and efficacious?

Expert Opinion on Pharmacotherapy

Volumn 15, Issue 3, 2014, Pages 437-441

  Doggrell, Sheila A ^a   McIntyre, Kerry ^a  

^a QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Canagliflozin; CANTATA SU; Clinical trials; HbA1c; Type 2 diabetes

Indexed keywords

CANAGLIFLOZIN; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSIGLITAZONE; SODIUM GLUCOSE COTRANSPORTER 2; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; JAPANESE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SEIZURE; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT INFECTION; VAGINA CANDIDIASIS; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; MALE; SODIUM-GLUCOSE TRANSPORTER 2; SULFONYLUREA COMPOUNDS; THIOPHENES;

EID: 84892716284     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2014.868885     Document Type: Article

References (18)

1. Ligaray KPL, Isley WL. Diabetes mellitus, type 2. Available from: http://emedicine.medscape.com/article/117853-overview [Last accessed 24 September 2013]
2. Koro CE, Bowlin SJ, Bourgeois N, Fedder DO. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 2004;27:17-20
3. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7
4. Stenlof K, Cefalu WT, Kim KA, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab 2013;15:372-82
5. Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013. [Epub ahead of print]
6. Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomized, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50
7. Doggrell SA. Clinical trials with thiazolidinediones in subjects with type 2 diabetes-is pioglitazone any different from rosiglitazone. Expert Opin Pharmacother 2008;9:405-20
8. Consoli A, Gormoso G. Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:967-77
9. Yale JF, Bakris G, Cariou B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab 2013;15:463-73
10. Rosenstock J, Aggarawal N, Polidori D, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care 2012;35:1232-8
11. Lavalle-González FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomized trial. Diabetologia 2013;56:2582-92
12. Johnsson KM, Ptaszynska A, Schmitz B, et al. Urinary tract infections in patients with diabetes treated with dapagliflozin. J Diabetes Complications 2013;27:473-8
13. FDA approves new diabetes drug, canagliflozin, despite CV concerns. Available from: http://theheart.org/article/1523789 [Last accessed 15 October 2013]
14. FDA news release: FDA approves Invokana to treat type 2 diabetes. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm345848.htm [Last accessed 8/10/2013]
15. Neal B, Perkovic V, de Zeeuw D, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS)-a randomized placebocontrolled trial. Am Heart J 2013;166:217-23
16. Experts express mixed thoughts on canagliflozin approval. Medscape. 2013. Available from: http://www. medscape.com/viewarticle/782712-print [Last accessed 14 November 2013]
17. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndromes in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35
18. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26